Payers Set Out Radical Wishlist For Changes To EU Pharma Legislation

European payers have called for fast-track approval pathways and only limited use of conditional approvals in the upcoming reform of the EU’s pharmaceutical legislation. They also want to see data and market protection periods reduced to boost competition.

Abstract train tunnel view in high speed — European Payers recommend limits on fast track approval processes • Source: Alamy

Forthcoming proposals from the European Commission on reforming the EU’s pharmaceutical legislation “should not mainstream” fast-track regulatory approvals and should limit the use of conditional marketing authorization, the European Social Insurance Platform (ESIP) and the Medicine Evaluation Committee (MEDEV) have warned.

The two groups also want to see amendments to the legislation that would improve access to medicines by boosting competition,...